Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01472081 · ClinicalTrials.gov registry record · Phase 1

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

A Phase 1 study of Renal Cell Carcinoma and Clear-cell Metastatic Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
194
Enrollment target
14
Study locations

NCT01472081 is a Phase 1 study of Renal Cell Carcinoma and Clear-cell Metastatic Renal Cell Carcinoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 194 participants, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (20% lower). The trial reports 14 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01472081, a Phase 1 study of Renal Cell Carcinoma and Clear-cell Metastatic Renal Cell Carcinoma, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
194 participants
Enrollment target
14
Study locations

Study Summary

The purpose is to determine the safety, effectiveness and best dose to use when giving Nivolumab in combination with Sunitinib, Pazopanib, or Ipilimumab for the treatment of metastatic renal cell carcinoma.

Conditions Studied

Renal Cell Carcinoma Clear-cell Metastatic Renal Cell Carcinoma

Interventions

  • DRUG Sunitinib
  • BIOLOGICAL Nivolumab
  • BIOLOGICAL Ipilimumab
  • BIOLOGICAL Pazopanib

Study Locations (14)

Alberta

  • Tom Baker Cancer Centre - Calgary
  • Cross Cancer Institute - Edmonton

California

  • City Of Hope - Duarte

Maryland

  • Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins - Baltimore

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

New Hampshire

  • Dartmouth-Hitchcock Medical Center - Lebanon

New York

  • Memorial Sloan Kettering Nassau - New York

North Carolina

  • Blumenthal Cancer Center - Charlotte

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 194 participants
Start Date 2012-02-09
Est. Completion 2021-06-03
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01472081

The ClinicalTrials.gov registry entry for NCT01472081 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (20% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Sunitinib is the first listed.

NCT01472081 reports 14 study locations spanning 13 distinct geographic areas - top geographies include Alberta, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT01472081 about?

NCT01472081 is a clinical study titled "Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)". The purpose is to determine the safety, effectiveness and best dose to use when giving Nivolumab in combination with Sunitinib, Pazopanib, or Ipilimumab for the treatment of metastatic renal cell carcinoma.

What is the current status of trial NCT01472081?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 194 participants. The study started on 2012-02-09. Estimated completion is 2021-06-03.

What conditions does trial NCT01472081 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma.

What interventions are being tested in trial NCT01472081?

The interventions under investigation include: Sunitinib (DRUG), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Pazopanib (BIOLOGICAL).

Who is sponsoring clinical trial NCT01472081?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01472081 being conducted?

This trial has 14 study locations across California, Maryland, Massachusetts, New Hampshire, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

Clear-cell Metastatic Renal Cell Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.